An updated patent review of p38 MAP kinase inhibitors (2014-2019)

P38 MAPK and glucocorticoid receptor crosstalk in bronchial epithelial cells

(2020) Simon Lea et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

MKK3 sustains cell proliferation and survival through p38DELTA MAPK activation in colorectal cancer

(2019) Lorenzo Stramucci et al.   Cell Death & Disease

Selective inhibition of the p38α MAPK–MK2 axis inhibits inflammatory cues including inflammasome priming signals

(2018) Chun Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Novel Noncatalytic Substrate-Selective p38α-Specific MAPK Inhibitors with Endothelial-Stabilizing and Anti-Inflammatory Activity

(2017) Nirav G. Shah et al.   JOURNAL OF IMMUNOLOGY

Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine

(2017) Niklas M. Walter et al.   JOURNAL OF MEDICINAL CHEMISTRY

p38MAPK/MK2-dependent phosphorylation controls cytotoxic RIPK1 signalling in inflammation and infection

(2017) Manoj B. Menon et al.   NATURE CELL BIOLOGY

The p38 pathway, a major pleiotropic cascade that transduces stress and metastatic signals in endothelial cells

(2017) Isabelle Corre et al.   Oncotarget

Identification of a Novel Inhibitory Allosteric Site in p38α

(2016) Patricia Gomez-Gutierrez et al.   PLoS One

Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management

(2015) Ryan A. Wilcox   AMERICAN JOURNAL OF HEMATOLOGY

Ten things you should know about protein kinases: IUPHAR Review 14

(2015) Doriano Fabbro et al.   BRITISH JOURNAL OF PHARMACOLOGY

A novel p38 MAPK docking-groove-targeted compound is a potent inhibitor of inflammatory hyperalgesia

(2014) Hanneke L. D. M. Willemen et al.   BIOCHEMICAL JOURNAL

p38 MAPK inhibitors: a patent review (2012 – 2013)

(2014) Stefanie Bühler et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Targeting the Hinge Glycine Flip and the Activation Loop: Novel Approach to Potent p38α Inhibitors

(2012) Kathrin E. Martz et al.   JOURNAL OF MEDICINAL CHEMISTRY

TGF- 1 Induces Endothelial Cell Apoptosis by Shifting VEGF Activation of p38MAPK from the Prosurvival p38  to Proapoptotic p38 

(2012) G. Ferrari et al.   MOLECULAR CANCER RESEARCH

p38α mitogen-activated protein kinase inhibitors, a patent review (2005 – 2011)

(2011) Stefan Fischer et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis

(2011) MARK C. GENOVESE et al.   JOURNAL OF RHEUMATOLOGY

Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor

(2011) Solveigh C Koeberle et al.   Nature Chemical Biology

Mechanisms and functions of p38 MAPK signalling

(2010) Ana Cuadrado et al.   BIOCHEMICAL JOURNAL

"Go upstream, young man": lessons learned from the p38 saga

(2009) D Hammaker et al.   ANNALS OF THE RHEUMATIC DISEASES

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

(2009) Stanley B. Cohen et al.   ARTHRITIS AND RHEUMATISM

Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes

(2008) Richard M. Angell et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Mycosis fungoides and Sézary syndrome

(2008) Sam T Hwang et al.   LANCET